{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:09:40Z","timestamp":1786118980563,"version":"build-2736575974"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,12,1]]},"DOI":"10.1097\/qai.0b013e31818cde21","type":"journal-article","created":{"date-parts":[[2008,11,13]],"date-time":"2008-11-13T03:11:21Z","timestamp":1226545881000},"page":"377-383","source":"Crossref","is-referenced-by-count":7,"title":["Improved Measures of Quality of Life, Lipid Profile, and Lipoatrophy After Treatment Interruption in HIV-Infected Patients With Immune Preservation: Results of ACTG 5170"],"prefix":"10.1097","volume":"49","author":[{"given":"Daniel J","family":"Skiest","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Krambrink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaohui","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin R","family":"Robertson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M","family":"Margolis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-5-20210131","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1001\/jama.286.20.2568","article-title":"Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy.","volume":"286","author":"Hogg","year":"2001","journal-title":"JAMA"},{"key":"R2-5-20210131","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1056\/NEJM199803263381301","article-title":"Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection.","volume":"338","author":"Palella","year":"1998","journal-title":"N Engl J Med"},{"key":"R3-5-20210131","doi-asserted-by":"crossref","first-page":"620","DOI":"10.7326\/0003-4819-138-8-200304150-00007","article-title":"Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata.","volume":"138","author":"Palella","year":"2003","journal-title":"Ann Intern Med"},{"key":"R4-5-20210131","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1001\/jama.1997.03540480062040","article-title":"Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel.","volume":"277","author":"Carpenter","year":"1997","journal-title":"JAMA"},{"issue":"RR-5","key":"R5-5-20210131","first-page":"43","article-title":"Kaiser Family Foundation. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents.","volume":"47","author":"Department of Health and Human Services and Henry","year":"1998","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R6-5-20210131","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1001\/jama.296.7.827","article-title":"Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel.","volume":"296","author":"Hammer","year":"2006","journal-title":"JAMA"},{"key":"R8-5-20210131","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1086\/512681","article-title":"Interruption of antiretroviral treatment in HIV-infected patients with preserved immune function is associated with a low rate of clinical progression: a prospective study by AIDS Clinical Trials Group 5170.","volume":"195","author":"Skiest","year":"2007","journal-title":"J Infect Dis"},{"key":"R9-5-20210131","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S0140-6736(06)69153-8","article-title":"CD4 guided scheduled treatment interruption compared to continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial.","volume":"368","author":"Ananworanich","year":"2006","journal-title":"Lancet"},{"key":"R10-5-20210131","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1016\/S0140-6736(06)68887-9","article-title":"CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in west Africa (Trivacan ANRS 1269 trial): a randomised trial.","volume":"367","author":"Danel","year":"2006","journal-title":"Lancet"},{"key":"R11-5-20210131","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1056\/NEJMoa062360","article-title":"CD4+ count-guided interruption of antiretroviral treatment.","volume":"355","author":"El-Sadr","year":"2006","journal-title":"N Engl J Med"},{"key":"R13-5-20210131","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1023\/A:1018460132567","article-title":"Applications of the Medical Outcomes Study health-related quality of life measures in HIV\/AIDS.","volume":"6","author":"Wu","year":"1997","journal-title":"Qual Life Res"},{"key":"R14-5-20210131","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1097\/01.aids.0000218547.39339.13","article-title":"Effect of long-cycle structured intermittent versus continuous HAART on quality of life in patients with chronic HIV infection.","volume":"20","author":"Powers","year":"2006","journal-title":"AIDS"},{"key":"R15-5-20210131","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1097\/01.qai.0000230321.85911.db","article-title":"Highly active antiretroviral therapy interruption: predictors and virological and immunologic consequences.","volume":"42","author":"Touloumi","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R16-5-20210131","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s11136-006-9151-7","article-title":"Health-related quality of life in HIV-1-infected patients on HAART: a five-years longitudinal analysis accounting for dropout in the APROCO-COPILOTE cohort (ANRS CO-8).","volume":"16","author":"Protopopescu","year":"2007","journal-title":"Qual Life Res"},{"key":"R17-5-20210131","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0002-9343(97)00349-5","article-title":"Constitutional symptoms and health-related quality of life in patients with symptomatic HIV disease.","volume":"104","author":"Cunningham","year":"1998","journal-title":"Am J Med"},{"key":"R18-5-20210131","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/00042560-199712150-00007","article-title":"Disease-related factors associated with health-related quality of life in people with nonadvanced HIV disease assessed using an Italian version of the MOS-HIV Health Survey.","volume":"16","author":"Murri","year":"1997","journal-title":"J Acquir Immune Defic Syndr Hum Retrovirol"},{"key":"R19-5-20210131","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/00002030-200001280-00014","article-title":"Quality of life in asymptomatic- and symptomatic HIV infected patients in a trial of ritonavir\/saquinavir therapy. The Prometheus Study Group.","volume":"14","author":"Nieuwkerk","year":"2000","journal-title":"AIDS"},{"key":"R21-5-20210131","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1097\/00126334-200208150-00004","article-title":"Relationship of HIV viral loads, CD4 counts, and HAART use to health-related quality of life.","volume":"30","author":"Gill","year":"2002","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R22-5-20210131","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1089\/apc.1999.13.185","article-title":"Predictors of self-reported adherence in persons living with HIV disease.","volume":"13","author":"Holzemer","year":"1999","journal-title":"AIDS Patient Care STDS"},{"key":"R23-5-20210131","doi-asserted-by":"crossref","first-page":"19041906","DOI":"10.1097\/00002030-200109280-00030","article-title":"Psychological impact of structured treatment interruptions in patients with prolonged undetectable HIV-1 viral loads.","volume":"15","author":"Tuldra","year":"2001","journal-title":"AIDS"},{"key":"R24-5-20210131","doi-asserted-by":"crossref","first-page":"337","DOI":"10.2174\/157016207780636506","article-title":"Effects of structured treatment interruptions on metabolic, anthropometric, immunologic, and quality of life outcomes in HIV-positive adults on HAART.","volume":"5","author":"Maserati","year":"2007","journal-title":"Curr HIV Res"},{"key":"R25-5-20210131","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1097\/QAI.0b013e31802f83bc","article-title":"Effects of active treatment discontinuation in patients with a CD4+ T-cell nadir greater than 350 cells\/mm3: 48-week Treatment Interruption in Early Starters Netherlands Study (TRIESTAN).","volume":"44","author":"Pogany","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R26-5-20210131","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/QAD.0b013e328011033a","article-title":"Antiretroviral therapy interruption guided by CD4 cell counts and plasma HIV-1 RNA levels in chronically HIV-1-infected patients.","volume":"21","author":"Ruiz","year":"2007","journal-title":"AIDS"},{"key":"R28-5-20210131","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0002-9343(02)01156-7","article-title":"Adverse effects of medications and trade-offs between length of life and quality of life in human immunodeficiency virus infection.","volume":"113","author":"Lenert","year":"2002","journal-title":"Am J Med"},{"key":"R29-5-20210131","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1097\/01.qai.0000167478.28051.3a","article-title":"Redefining lipodystrophy syndrome: risks and impact on clinical decision making.","volume":"39","author":"Lichtenstein","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R30-5-20210131","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1001\/jama.289.22.2978","article-title":"Impact of HIV infection and HAART on serum lipids in men.","volume":"289","author":"Riddler","year":"2003","journal-title":"JAMA"},{"key":"R31-5-20210131","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1086\/507333","article-title":"Current concepts in the diagnosis and management of metabolic complications of HIV infection and its therapy.","volume":"43","author":"Wohl","year":"2006","journal-title":"Clin Infect Dis"},{"issue":"21","key":"R32-5-20210131","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJMoa030218","article-title":"Combination antiretroviral therapy and the risk of myocardial infarction.","volume":"349","author":"Friis-Moller","year":"2003","journal-title":"N Engl J Med"},{"key":"R33-5-20210131","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa062744","article-title":"Class of antiretroviral drugs and the risk of myocardial infarction.","volume":"356","author":"Friis-Moller","year":"2007","journal-title":"N Engl J Med"},{"key":"R34-5-20210131","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1468-1293.2005.00265.x","article-title":"Protease inhibitor exposure and increased risk of cardiovascular disease in HIV-infected patients.","volume":"6","author":"Iloeje","year":"2005","journal-title":"HIV Med"},{"key":"R35-5-20210131","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/00002030-200501280-00015","article-title":"Prolonged treatment interruption in chronic HIV infection: a new strategy?","volume":"19","author":"Giuntini","year":"2005","journal-title":"AIDS"},{"key":"R36-5-20210131","first-page":"287","article-title":"CD4 cell-monitored treatment interruption in patients with a CD4 cell count 500 106 cells\/l.","volume":"19","author":"Mussini","year":"2005","journal-title":"AIDS"}],"container-title":["JAIDS Journal of Acquired Immune Deficiency Syndromes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/QAI.0b013e31818cde21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:13:35Z","timestamp":1786036415000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00126334-200812010-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12,1]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/qai.0b013e31818cde21","relation":{},"ISSN":["1525-4135"],"issn-type":[{"value":"1525-4135","type":"print"}],"subject":[],"published":{"date-parts":[[2008,12,1]]}}}